We have shown earlier that a single dose of cloned defective interfering (DI) influenza A virus strongly protects mice from disease following a lethal challenge with different subtypes of influenza A virus. These animals suffered no clinical disease but experienced a subclinical infection which rendered them immune to reinfection with the same challenge virus.
Introduction
In the course of replication most viruses make defective-interfering (DI) viruses, which are virus particles composed of a normal set of viral proteins encapsidating a deleted version of the viral genome. Because they lack essential genetic information, DI viruses are replication deficient. Replication of the defective genome is achieved by the presence in the same cell of a genetically compatible infectious genome, usually from the virus that generated the DI genome, and which provides the missing function(s) in trans. DI virus is thus totally dependent on infectious virus for replication. Interference occurs when the ratio of defective: infectious genomes increases to a level which results in a reduction of the amount of infectious virus produced [1] [2] [3] [4] [5] . Most of our knowledge comes from studies in cultured cells, but there is also limited evidence that DI virus can protect against virus diseases in vivo [6] [7] [8] [9] [10] . The conventional view, developed by extrapolation from in vitro studies, is that the protection afforded in vivo is also due to competition between the DI and infectious viruses at the level of genome replication. However, in those cases where in vivo protection has been seen there is little direct evidence for this or any other mechanism.
Influenza A viruses have a genome that comprises 8 separate segments of single stranded, negative sense RNA. DI influenza viruses arise readily and their study has a long history extending back over 60 years [5, [11] [12] [13] . DI RNAs can potentially arise from all viral segments, but are most commonly derived from segments 1-3. All influenza DI RNAs formed from their cognate RNA and contain a large central deletion of approximately 80%, but retain the terminal sequences which control replication and packaging. It is hypothesized that an infectious particle packages one of each of full-length segments 1-8, while the DI virus particle packages a DI RNA in place of its cognate full-length RNA, plus the other 7 full length RNAs. Most DI influenza virus preparations contain many different DI RNA sequences, but it is not known if a single DI particle can contain more than one DI RNA, or if there are other DI particles in the preparation that contain a DI RNA derived from a different segment. The position and extent of the central deletion in the DI RNA is highly variable so that DI RNAs originating from one genomic segment can have many different sequences. For all these reasons it has been difficult to determine the relationship between a DI RNA sequence and the biological properties of the DI virus [14] . We recently solved this problem by using molecularly or biologically cloned viruses that contain one major species of DI RNA [14] [15] [16] [17] [18] , and subsequently characterized one DI virus, containing RNA 244, that strongly protects mice from clinical disease caused by various influenza A virus subtypes [18] .
However, it is not understood how influenza DI virus mediates such protection in vivo. In principle, DI viruses could act in vivo by interfering with the production of homologous virus (as described above), by stimulating adaptive immune responses, by stimulating innate immune responses, or by means as yet unknown. More than one of these mechanisms may operate at any one time. We have shown previously that various aspects of the humoral and T cell-mediated arms of murine adaptive immunity interact with infectious virus in the presence of non-cloned DI influenza A virus. The data showed that the responses to infection were modified in several unusual ways by the presence of active DI virus (see Discussion) [19] [20] [21] [22] [23] [24] [25] .
Here we investigate how severe combined immunodeficient (SCID) mice that completely lack adaptive immunity but retain NK cell activity respond to a mixture of infectious virus and in conjunction with treatment with cloned DI virus that confers protection from disease in immune-competent animals. SCID mice have been used extensively for investigating the role of the immune system in recovery from influenza virus infections [26] [27] [28] [29] [30] [31] .
Analysis of the mechanism(s) by which DI viruses prevent disease in treated animals is not fully understood. The DI influenza virus particle and its component proteins are indistinguishable from those of infectious virus and, in principle, they may be capable of stimulating a similar adaptive immunity as to that resulting from exposure seen with to a conventional inactivated influenza virus vaccines. The data show that adaptive immunity is not required for DI virus to protect SCID mice from acute influenza. However, in contrast to immune-competent animals, a delayed onset disease occurred about one week later, indicating that adaptive immunity is required to act in concert with DI virus to clear the infection.
Materials and methods

Production of 244 DI virus by reverse genetics
The 244 DI RNA used here to protect mice was originally generated spontaneously during transfection of 293T cells with plasmids [32] to make infectious influenza A/PR/8/34 [18] .
After 24 h, the 293T cells were trypsinized, mixed with MDCK cells and re-plated, and culture supernatants harvested 7 days later. Resulting virus was passaged twice in embryonated chicken's eggs. The resulting mixture of 244 DI virus, packaged in a A/PR8 particle, and infectious helper A/PR8 virus was purified by differential centrifugation through sucrose. Stocks were resuspended in PBS containing 0.1% w/v bovine serum albumin, standardized by haemagglutination titration, and stored in liquid nitrogen. Before inoculation into mice, helper virus infectivity was eliminated with a short burst (40 seconds) of UV irradiation at 253.7 nm (0.64 mW/cm 2 ). This is referred to as 'active DI virus'. The UV inactivation target is viral RNA, and UV has little effect on the DI RNA because of its small target size, 395 nt compared with 13,600 nt for infectious virus. Longer UV irradiation (8 minutes) inactivated mouse-protecting activity and provided a preparation that controlled for any immune system-stimulating or receptor-blocking effects ('inactivated DI virus').
However, UV treatment did not completely destroy all DI RNA. UV did not affect haemagglutinin or neuraminidase activities.
Mice
We GGATTGGTCTTGTCTTTAGCCA 3') and probe (5' FAM-CTCGGCTTTGAGGGGGCCTGA 3') [35] . Primers were synthesized by Invitrogen, and the probes by ABI. To distinguish the 244 segment 1 DI RNA from full-length segment 1, a probe was designed to cover the DI RNA junction region formed when the terminal segment 1 fragments were ligated, and which is absent from full-length RNA. A unique segment 1 probe was designed from the region which has been deleted from 244 DI RNA. A standard for each virion-sense RNA stock was made by subcloning PCR products of either full length RNA or the region flanking the amplicon in pGEMT-easy vector (Promega). RNA was transcribed using the T7 or SP6 RNA polymerase (MEGAscript, Ambion), the mix was digested with DNase I, and RNA purified by electro-elution. After ethanol precipitation, RNA was resuspended into RNase-free water and quantitated on a Nanodrop 1000 (Thermoscientific, Wilmington, DE). Standard curves were generated by performing 10-fold serial dilutions of known RNA copy numbers with each dilution assayed in triplicate. The reaction was conducted at 50°C for 2 min, 95°C for 10 min, then 40 cycles of 94°C for 15 sec followed by 60°C for 1 min.
Infectivity assay
The right-hand lung from each infected mouse was homogenised with sand in PBS containing 0.1% w/v BSA, and centrifuged to remove debris. A/WSN infectivity was titrated in a focusforming assay using MDCK cells in 96-well plates in triplicate. Cells were incubated at 33°C
for 18 hours, fixed in 4% v/v formaldehyde, and blocked with 5% w/v milk powder in PBS.
Virus-positive cells were detected using a mouse monoclonal antibody specific for the A/WSN haemagglutinin, and a goat anti-mouse IgG -alkaline phosphatase conjugate (Sigma), both in buffered saline containing 0.1% v/v Tween, and finally incubated with an alkaline phosphatase substrate (NBT/BCIP in TMN buffer; Sigma). At least 50 stained cells (foci) at an appropriate dilution were counted in each of three wells and averaged to give a titre in focus-forming units (FFU)/lung.
Results
SCID mice are protected from acute influenza by DI virus, but eventually develop a delayed onset disease
Before examining SCID mice we tested the infection parameters of A/WSN in the immune competent Balb/c strain from which they had been derived. Mice inoculated simultaneously with 1.2 µg of active DI virus and infected with A/WSN were either completely protected or suffered only a mild clinical disease of short duration with slight weight loss (Fig. 1a, b) . In contrast mice inoculated simultaneously with the same amount of inactivated DI virus and A/WSN lost 19% of body weight at the peak of infection (Fig. 1a) ; all became seriously ill but then recovered (Fig. 1b) . After recovery mice in all groups remained healthy and continued to gain weight with no untoward signs for the duration of the experiment (19 days).
Such mice were immune to rechallenge with high dose A/WSN [18] (data not shown). There was essentially no difference in disease progression between mice inoculated intranasally with A/WSN and mice inoculated with inactivated DI virus + A/WSN (data not shown).
SCID mice infected with A/WSN succumbed to a disease similar to that seen in immunecompetent Balb/c mice as judged by clinical signs and weight loss from day 3 after infection, progressing to death or to the point at which they had to be euthanized (Fig. 1c, d ). The dynamics of disease were very similar in SCID mice inoculated intranasally with 1.2 µg ( SCID mice which had been protected from influenza by treatment with 1.2 µg of active DI virus all remained well for 9 days, but on day 10 some started to lose weight and show signs of disease (Fig. 1c, d ). The mice developed severe respiratory symptoms and continued weight loss and progressed to death or euthanasia (Fig 1c, d) . SCID mice treated with a higher DI dose (12 µg) remained well for 14 days, but started to lose weight and become ill on day 15 ( Fig. 1 e, f) . At both doses the delayed onset disease had similar dynamics in terms of clinical signs, severity, and duration to the acute influenza seen in SCID mice infected with virus alone. This indicates that the adaptive immune response plays an important role in the late stages of DI virus-mediated protection from influenza virus infection in vivo.
DI virus retards lung consolidation and accumulation of infectious virus load in the lungs of SCID mice.
To understand how DI virus mediated protection we examined mice for lung consolidation and lung infectivity. Protection conferred by 1.2 µg of active DI virus ( and at day 8 there was overt lung consolidation (Fig. 2c) . Consolidation, infectious virus load, weight loss and clinical disease all increased thereafter (Fig. 2 a, b, c, d ). Taken together, the data show that active DI virus treatment significantly delayed the production of infectious virus in the lungs of SCID mice compared to those treated with inactive DI virus and this correlated with delays in the lung consolidation and overt clinical disease.
The delayed onset disease in active DI virus-treated SCID mice is not due to lung DI
RNA declining in amount or undergoing mutation
There are no reports in the literature for the dynamics of influenza full-length or DI RNA synthesis in the mouse lung. To determine if the delayed disease was due to changes in the levels of 244 DI or infectious virus RNA, total RNA was isolated from the lungs of each group of SCID mice described in Fig. 2 and subjected to real-time PCR to determine the amounts of 244 DI RNA, genomic segment 1 RNA, and segment 7 RNA (Fig. 3) . RNA and residual intact 244 RNA (Fig 3c, d ). After 2 days there was undetectable 244 DI RNA in the lungs of mice inoculated with inactivated DI virus + A/WSN (Fig. 3c, d ), whereas the amount in the active DI virus + A/WSN group was unchanged. 244 RNA in the active DI virus-protected group then maintained a modest but steady rise to nearly 10 9 copies per lung by day 8, and remained between 10 8 -10 9 copies until day 16 when most of the mice were dead.
The RNA was clearly being replicated as mice that received only active DI virus showed a steady decline in amounts of 244 RNA (Fig. 3d open squares) . Thus substantial amounts of 244 RNA were present in mice inoculated with DI + A/WSN throughout both the initial period of good health (up to and including day 9) and through the period of delayed onset disease (days 10-16). In contrast 244 DI RNA in the lungs of mice inoculated with inactivated DI virus + A/WSN increased from day 2 to day 4 reflecting rapid replication of residual amounts of DI RNA that remained after the UV-irradiation (Fig. 3c) . The 244 RNA increased to a maximum on day 6, but this was evidently too late to be of benefit as 75% of mice already showed signs of clinical disease on day 4.
Although 244 DI RNA was replicated in the lungs of A/WSN-infected SCID mice that were initially protected from acute disease, it was possible that at some stage the 244 DI RNA To test this possibility we isolated infectious virus from the lungs of severely ill SCID mice at 16 days after inoculation with active DI virus + A/WSN (Fig. 1) . Virus was passed once in MDCK cells (to produce SCID/WSN-DI virus), purified as described in Methods, and titrated in MDCK cells alongside the original A/WSN challenge virus. The SCID/WSN-DI virus (Fig. 4a, b) was then compared with the original A/WSN challenge virus (Fig. 4c, d ) at the same infectivity titre (2. Table 1 . In the acute disease, significant weight loss and clinical signs coincided with or occurred 1 day later than infectivity reaching approximately 10 6 ffu in the lung, with consolidation commencing 1 to 2 days later. In contrast, mice treated with DI virus attained similar levels of infectivity and significant consolidation on day 8, but significant weight loss and clinical signs were not apparent for another 3 days. However, once initiated the course of disease in the acute and late onset disease groups was indistinguishable. We have not seen any relapse in many hundreds of wild-type mice, with no known immune defect, protected with 244 DI virus from various influenza A viruses, and this includes observing most mice for 7 weeks and some for 6 months after infection (authors' unpublished data). Lung consolidation in SCID mice infected with an influenza A virus is described as plum coloured areas on the lung surface (as we found), which microscopically presents as a proliferative pneumonia, comprising a massive multifocal to coalescing proliferative bronchitis, bronchiolitis, and alveolitis, marked proliferation of type II pneumocytes, and hyperplastic and hypertrophic columnar epithelium lining the airways [26] . A substantial migration of natural killer cells into the lungs of influenza virus-infected SCID mice has also been reported, although they played no role in disease progression [27] . In mice given a 10-fold higher DI dose, disease was delayed by a further 7 days showing that the delay was DI virus dose-dependent (Fig. 1d, f) . Nonclearance of infectivity is the norm in influenza virus-infected SCID mice [28, 29, 31] , not unexpectedly as immune competent mice require B and T cell responses to clear influenza infection [45] [46] [47] .
Delayed onset disease in active DI virus-treated SCID mice is not due to challenge virus becoming resistant to DI virus
Previous work using wild-type mice, A/WSN challenge virus, and non-cloned DI WSN virus
showed that there were MHC-restricted virus-specific CD8 + and CD4 + CTL responses in the lungs of H-2 k mice infected with A/WSN or A/WSN + inactivated DI virus. These mice all died. CTL responses were diminished in mice inoculated with A/WSN + DI virus and these all survived [19] . Analysis of the specificity of T cell responses using vaccinia viruses expressing individual influenza A virus proteins showed that, unusually for influenza A virus infections, the response in A/WSN-infected, DI virus-treated mice was largely strain specific.
Depletion of both CD8 + and CD4 + cells with specific antibody was needed to abolish lung consolidation and for mice infected with A/WSN or A/WSN + inactivated DI virus to survive [19] , but like the SCID mice reported here, infectious virus in the lung was not cleared. In contrast, when mice depleted of CD8 + and CD4 + cells were inoculated with A/WSN + DI virus, lung infectivity was cleared, presumably with the assistance of local, T cellindependent, virus-specific antibody. These mice produced a haemagglutinin (HA)-specific antibody that was highly unusual as it was was not neutralizing but, when adoptively transferred, protected naïve animals from A/WSN [20, 22, 25] . The same HA-specific lung the virus selectively packaging one copy of each of the 8 segments [48] . Thus, packaging of the DI RNA would prevent packaging of the segment from which it was derived and would very efficiently render that virus particle non-infectious. The data presented here also indicate that adaptive immunity is not required for prevention of acute infection in SCID mice but is needed to prevent disease breaking out later. This was not due to genome competition between the segment 1 DI RNA and its cognate full-length segment. In other experiments we have found that 244 RNA fully protects type I interferon receptor null mice from disease resulting from A/WSN infection [49] . However, the possibility that interferon also plays a role in DI-mediated protection of SCID mice has yet to be determined. 
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